195 related articles for article (PubMed ID: 30900392)
1. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.
Mora J; Valero M; DiCristina C; Jin M; Chain A; Bickham K
Pediatr Blood Cancer; 2019 Jun; 66(6):e27690. PubMed ID: 30900392
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
3. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial.
Radhakrishnan V; Joshi A; Ramamoorthy J; Rajaraman S; Ganesan P; Ganesan TS; Dhanushkodi M; Sagar TG
Pediatr Blood Cancer; 2019 Mar; 66(3):e27551. PubMed ID: 30426714
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
[TBL] [Abstract][Full Text] [Related]
5. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
6. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL; Jordan K; Weinstein C
Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
8. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
Garnock-Jones KP
Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Cabanillas Stanchi KM; Vek J; Schlegel P; Rupprecht JV; Flaadt T; Weber S; Michaelis S; Lang P; Handgretinger R; Döring M
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1089-1100. PubMed ID: 32056007
[TBL] [Abstract][Full Text] [Related]
10. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
Choi MR; Jiles C; Seibel NL
J Pediatr Hematol Oncol; 2010 Oct; 32(7):e268-71. PubMed ID: 20736848
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of aprepitant and fosaprepitant in pediatric patients.
Saito Y; Kumamoto T; Arima T; Shirakawa N; Ishimaru S; Sonoda T; Nakajima M; Sugiyama M; Arakawa A; Hashimoto H; Makino Y; Ogawa C; Yamaguchi M
Pediatr Int; 2019 Mar; 61(3):235-239. PubMed ID: 30615239
[TBL] [Abstract][Full Text] [Related]
12. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
[TBL] [Abstract][Full Text] [Related]
13. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
Kang HJ; Loftus S; Taylor A; DiCristina C; Green S; Zwaan CM
Lancet Oncol; 2015 Apr; 16(4):385-94. PubMed ID: 25770814
[TBL] [Abstract][Full Text] [Related]
16. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic evaluation of fosaprepitant dimeglumine.
Colon-Gonzalez F; Kraft WK
Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1277-86. PubMed ID: 20795794
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Saito H; Yoshizawa H; Yoshimori K; Katakami N; Katsumata N; Kawahara M; Eguchi K
Ann Oncol; 2013 Apr; 24(4):1067-73. PubMed ID: 23117073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
